WO2014010658A1 - ヒハツ配合製剤 - Google Patents
ヒハツ配合製剤 Download PDFInfo
- Publication number
- WO2014010658A1 WO2014010658A1 PCT/JP2013/068934 JP2013068934W WO2014010658A1 WO 2014010658 A1 WO2014010658 A1 WO 2014010658A1 JP 2013068934 W JP2013068934 W JP 2013068934W WO 2014010658 A1 WO2014010658 A1 WO 2014010658A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nausea
- ethanol
- turmeric
- gastrointestinal
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
Definitions
- the present invention relates to a drug having an excellent gastrointestinal mucosa protective action and antiemetic action. More specifically, excellent gastrointestinal mucosal protective action against gastrointestinal mucosal damage due to ethanol overdose, stress, overdose, smoking, and nonsteroidal anti-inflammatory drugs, and nausea, nausea or The present invention relates to a drug having an excellent antiemetic action against vomiting.
- Non-patent Document 1 a gram-negative bacilli
- Non-patent Document 2 Shay's balance theory
- antibiotics having anti-Helicobacter pylori activity for example, penicillin, ampicillin, erythromycin, clarithromycin, streptomycin, tetracycline, etc.
- bismuth preparations are used for the treatment of peptic ulcer caused by Helicobacter pylori. .
- the mechanism of peptic ulcer caused by an imbalance of attack and defense factors such as hyperacidity is different from that caused by Helicobacter pylori as described above.
- This includes gastrointestinal mucosa such as overdose of ethanol, stress, dysphagia, smoking, and nonsteroidal anti-inflammatory drugs (aspirin, acetaminophen, ibuprofen, indomethacin, etenzamide, tranexamic acid, loxoprofen, etc.)
- gastric acid which is an attack factor, becomes relatively excessive due to a reduction in the protective power of the stomach and duodenal mucosa, etc., and damages the gastrointestinal mucosa.
- gastric acid secretion inhibitors and anti-pepsin agents which are attack factor inhibitors, or mucosal protective agents and tissue repair promoters, which are defense factor enhancers, are used for this treatment.
- the cause of ulcers in the upper body of the stomach and relapsed refractory ulcers seen in elderly people is often a decrease in protective factors, and it is desired to provide an excellent protective factor enhancer.
- Patent Document 1 a blend of processed potato, carrot and antacid
- Patent Document 2 a blend of oxon, turmeric and shochu
- Hihatsu has the scientific name Piper longum L. Or it is called Pipe retrofractum Vahl and is a plant belonging to the genus Pepperaceae.
- the dried product of immature fruit spikes has been widely used as a spice with an appetite since ancient times.
- Hihatsu is also known as a herbal medicine with analgesic / healthy stomach action, blood flow increasing action, antibacterial action, etc., and is used as an antibacterial agent against Helicobacter pylori (Patent Document 3) and as a functional gastroenteropathy treatment agent. It is reported that it is effective for use as a cold improver (Patent Document 5), as a swelling improver (Patent Document 6).
- baboon is an irritating herbal medicine and enhances gastrointestinal function and promotes gastric acid secretion, so it is not used for the treatment of inflammatory or ulcerative diseases.
- baboons affect nausea, nausea or vomiting due to ethanol overdose.
- the present inventors have conducted extensive research, and as a result, found that hihatsu has an excellent gastrointestinal mucosal protective action, and that when combined with turmeric, a synergistic effect can be obtained.
- the present invention has been completed.
- the inventor has also found that baboon has an excellent antiemetic action against nausea, nausea or vomiting caused by excessive intake of ethanol, and has completed the present invention. That is, the present invention provides a gastrointestinal mucosal protective agent (hereinafter referred to as the gastrointestinal mucosal protective agent of the present invention) containing hihatsu.
- the present invention provides an antiemetic containing hihatsu (hereinafter referred to as an antiemetic of the present invention).
- medical agent which has the outstanding digestive tract mucosa protective effect can be provided.
- a drug having an excellent gastrointestinal mucosal protective action against gastrointestinal mucosal damage caused by ethanol can be provided. It can be effectively applied to the improvement of various unpleasant symptoms such as stomach pain, nausea and stomach weight after ingestion of ethanol.
- gastrointestinal mucosal damage caused by stress, heavy drinking and eating, smoking, and nonsteroidal anti-inflammatory drugs can be significantly suppressed.
- the antiemetic which has the improvement effect excellent with respect to nausea, nausea, or vomiting can be provided. More specifically, it is possible to provide an antiemetic having an excellent improving effect on nausea, nausea or vomiting caused by ethanol intake.
- the present invention has an excellent ameliorating action particularly on gastrointestinal mucosal damage and vomiting caused by ingestion of ethanol, and therefore can be effectively used as an agent for improving discomfort caused by ingestion of ethanol.
- the gastrointestinal mucosa protective agent or antiemetic of the present invention contains hihatsu.
- baboon refers to baboon (Piper longum L. (aka: Indiana pepper) or Piper retrofractum Vahl (aka: Javanaga pepper).
- Hibatsu is also called Naga Pepper (long pepper), and there is a literature that uses Java Naga Pepper as Hihatu modo in order to distinguish it from Hibatsu in a narrow sense, but in the present invention, Treat both as hihatsu.
- Hibatsu those made from mature or immature fruit spikes, leaves, petioles, branches, roots, etc. are used.
- the hihatsu used in the present invention is its fruit head or immature fruit head.
- These can be used in the form of dried extract powder, which has been appropriately dried, or an extract extracted with water, lower alcohol or a mixed solvent thereof.
- Specific examples include hihatsu, hihatsu powder, hihatsu extract, hihatsu-style extract, hihatsu dried extract, hihatsu soft extract, and the like.
- Examples of commercially available products include Hihatsu powder (manufactured by Mikuni Co., Ltd.), Hihatsu extract MF (manufactured by Maruzen Pharmaceutical Co., Ltd.), and the like.
- Hibatsu used in the present invention is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight in terms of the active ingredient based on the preparation. If this blending amount is less than 0.001% by weight, the effect may be low, and if it exceeds 10% by weight, irritation such as pungency becomes strong, which may be undesirable from the viewpoint of taking feeling.
- the daily use amount of Hihatsu per adult can be used within the range of 5 g / day, preferably 3 g / day, in terms of the active ingredient, but the single dose is usually 0.001 to The amount is preferably 2 g, preferably in the range of 0.01 to 1 g.
- turmeric can be used in combination.
- the turmeric in this case is Ginger family turmeric (Curcuma longa (also known as autumn turmeric) or Curcuma aromatica (also known as spring turmeric)).
- autumn turmeric and spring turmeric can be used, but it is preferable to use autumn turmeric.
- Turmeric used in the present invention is preferably rhizome as it is or boiled except for pericarp, and further extracted with powdered turmeric powder, water, lower alcohol or a mixed solvent thereof. What was made into the extracted extract is still more preferable.
- Specific examples include turmeric, turmeric powder, turmeric extract, turmeric extract, turmeric dry extract, turmeric soft extract, and fermented turmeric, and turmeric powder or turmeric extract is preferred.
- examples of commercially available products include turmeric powder (manufactured by Nippon Powder Chemical Co., Ltd.), turmeric extract (manufactured by Nippon Powder Chemical Co., Ltd., Maruzen Pharmaceutical Co., Ltd.), and the like.
- turmeric When turmeric is used together in the present invention, it is preferably 0.1 to 60% by weight, more preferably 0.5 to 30% by weight in terms of the active ingredient based on the preparation. If the blending amount is less than 0.1% by weight, the effect may be low. If the blending amount exceeds 60% by weight, the astringency becomes strong, which is not preferable in terms of taking feeling.
- the amount of turmeric used per day for an adult can be used in the range of 10 g / day, preferably 6 g / day, in terms of the active ingredient, but the single dose is usually 0.01 to 1 in terms of the active ingredient. The amount is preferably 6 g, preferably in the range of 0.1 to 2 g.
- the weight ratio of baboon to turmeric is preferably 1: 0.01 to 1: 120, and 1: 0.1 to 1:60 in terms of the active ingredient. Is more preferable, and 1: 1 to 1:10 is particularly preferable.
- the gastrointestinal mucosal protective agent or antiemetic containing the rabbit of the present invention can be used as a remedy for discomfort caused by ingestion of ethanol, either after ingestion of ethanol (especially the next day), before ingestion of ethanol or even during ingestion of ethanol.
- the gastrointestinal mucosa protective agent or antiemetic of the present invention is preferably taken orally.
- the gastrointestinal mucosa protective agent of the present invention can be used for the treatment or prevention of gastrointestinal mucosal disorder or peptic ulcer, and in particular, digestive tract mucosal damage after ethanol intake, digestion caused by excessive intake of ethanol.
- Excellent therapeutic or preventive effects are observed for gastrointestinal ulcers or gastrointestinal mucosal disorders and peptic ulcers caused by stress, heavy drinking and eating, smoking, and nonsteroidal anti-inflammatory drugs.
- it can be effectively applied to improve unpleasant symptoms such as gastric pain, nausea, and stomach weight after ingestion of ethanol or after stress, heavy drinking and eating, smoking, and taking non-steroidal anti-inflammatory drugs. .
- the gastrointestinal mucosa includes gastric mucosa or duodenal mucosa.
- the antiemetic of the present invention is used for suppressing or preventing nausea, nausea or vomiting, and can be applied as an antiemetic for nausea, nausea or vomiting associated with the following causes or diseases.
- the causes or diseases of nausea, nausea or vomiting include ethanol overdose, stress, motion sickness, food poisoning, cold body, pregnancy (morning), accidental ingestion of foreign bodies, side effects due to drugs, acute gastritis, stomach Duodenal ulcer, appendicitis, bowel obstruction, acute peritonitis, pancreatitis, migraine, Meniere disease, cerebral hemorrhage, brain tumor, subarachnoid hemorrhage, acute cholecystitis, acute hepatitis, alcoholic hepatitis, cholelithiasis, gastric polyp, fatty liver, pneumonia, glaucoma, Or chronic subdural hematoma etc. are mentioned.
- the gastrointestinal mucosa protective agent or antiemetic of the present invention can be preferably used as a discomfort symptom improving agent by ingesting ethanol.
- the unpleasant symptom caused by ingestion of ethanol means stomach pain, nausea, stomach weight, nausea, nausea or vomiting caused by ingestion of ethanol.
- alcohol is synonymous with ethanol.
- the gastrointestinal mucosa protective agent or antiemetic of the present invention may be used in combination with other gastrointestinal mucosa protective agent or antiemetic.
- the gastrointestinal mucosa protective agent or antiemetic of the present invention may further contain the following active ingredients and additives as necessary. Active ingredients include other gastrointestinal mucosal protective agents, other antiemetics, blood alcohol level lowering accelerators, antacids, stomachic agents, liver function improving agents, digestive agents, intestinal regulating agents, antipruritics, analgesic antispasmodics, gastric mucosa Examples include restoration agents, vitamins, and antifoaming agents.
- Examples of the blood alcohol concentration lowering promoter include turmeric, amino acids (alanine, glutamine), rainbow trout, cordyceps, citrus molasses (derived from Wenzhou oranges), ⁇ -lactalbumin, lactulose, maltitol, lactitol, glycerol, oleanolic acid, Presenegenin, Hederagenin, Protoesigenin, Caffeine, Chixetsunin, Kyokyo, Carnitine chloride, Glycylglycine, Pepino, Kuzune, Mung bean, Red bean, Santo, Malt, Kawamata, Kashiwa, Akiko, Sandhi, Light load, Fructose, Ginseng , Komi-sou hot water or Kazuwa-to fermented lactic acid bacteria, guava, dry activated yeast, fructose, ascorbic acid, aroma substance, citric acid, kinin and the like.
- amino acids alanine, glut
- antacids include synthetic hydrotalcite, magnesium oxide, magnesium silicate, magnesium aluminate silicate, aluminum silicate, magnesium aluminate metasilicate, magnesium hydroxide, aluminum hydroxide, magnesium alumina hydroxide, dihydroxy Aluminum aminoacetate, sodium hydrogencarbonate, calcium carbonate, magnesium carbonate, calcium hydrogenphosphate, aminoacetic acid, funnel extract and the like can be mentioned.
- stomachic agent for example, anise, aloe, fennel, yak, turmeric, life-grass, ogon, oak, auren, processed garlic, garlic, cuckoo, columnar root, psoriasis, rice husk, pheasant, keihi, gentian, Koujin, Kokuboku, Goshuyu, Pepper, Colombo, Conzurango, Sanshishi, Salamander, Yamana, Shisoshi, Shukusha, Shokyo, Shozu, Green peel, Ishizone, Centaurium grass, Assembly, Sowjutsu, Soyo, Daisuke, Daio, Takusha, Chiku Setu carrot, clove, chorei, chimpi, capsicum, spruce, animal gall (including yutan), oyster mushroom, nutmeg, carrot, mint (including Atlantic mint), peanut, broomfish, hops, honey extract, rape leaves (Saisai), Mokk
- liver function improving agent examples include, for example, liver hydrolyzate, Maria thistle, Tabana carrot, turmeric, indigo, dandelion, western dandelion, burdock, garlic, chrysanthemum, yarrow, gardenia, sesame, asparagus, onion, chicory, Medicinal salvia, Korean thistle (artichoke), wolfberry, legumes / iridaceae / rose family plants (eg, soybeans and kudzu, asparagus linearias belonging to legumes), Japanese quail, elba de pasarinho, cetesangria, red buds, Black tea, Saiko, Peach seed, Peony skin, Safflower, Sanjyo, Gadju, ⁇ -lipoic acid, Flavonols, Flavones, Flavans, Flavanols, Catechins, Isoflavones, Lignanoic acid, Curcuminoids, Gluterin, Prolamin, Glutathione
- Examples of the digestive agent include starch digestive enzyme, protein digestive enzyme, fat digestive enzyme, fibrin digestive enzyme, ursodesoxycholic acid, oxycoranoates, cholic acid, bile powder, bile extract (powder), dehydrocol Acid, animal gall (including yutan) and the like.
- intestinal adjusting agent examples include live intestinal fungi components, natto kinase, akame koji, asenyaku, aloe, ubai, ketsumeishi, genokosho, plantago obata and the like.
- Antidiarrheal agents include, for example, acrinol, berberine chloride, guaiacol, creosote, phenyl salicylate, guaiacol carbonate, berberine tannate, bismuth hyposalicylate, bismuth nitrate, bismuth carbonate, bismuth gallate, tannic acid, albumin tannate , Methylene thymol tannin, kaolin, pectin, medicinal charcoal, calcium lactate, Acacia yam, buckwheat, duckweed, auren, kudin, ganodermone, pentaploid, hawthorn, yellowtail, ivy.
- analgesic and antispasmodic agents include oxyphencyclimine hydrochloride, dicyclomine hydrochloride, methixene hydrochloride, scopolamine hydrobromide, methyl atropine bromide, methyl anisotropine bromide, methyl scopolamine bromide, butyl scopolamine bromide, methyl bromide- l-hyostiamine, methylbenactidium bromide, belladonna extract, belladonna total alkaloid, iodopropamide, diphenylpiperidinomethyldioxolane iodide, funnel extract, funnel root total alkaloid citrate, papaverine hydrochloride, engosac, licorice, Examples include kokuboku and peonies.
- gastric mucosa repairing agent examples include sodium azulenesulfonate, aldioxa, glycyrrhizic acid and salts thereof, and licorice extract, L-glutamine, copper chlorophyllin potassium, copper chlorophyllin sodium, histidine hydrochloride, porcine gastric wall pepsin degradation product, porcine gastric wall acid Hydrolysates, methylmethionine sulfonium chloride, red buds, engosac, licorice, sucralfate, rebamipide, marzulene, polaprezinc, sodium alginate, gefarnate, teprenone, troxipide, benexate betadex, prunotol, irsogladine maleate, sofalcone, etc. It is done.
- vitamins include nicotinic acid amide, calcium pantothenate, biotin, vitamin B 1 or a derivative or salt thereof, vitamin B 2 or a derivative or salt thereof, vitamin B 6 or a derivative or salt thereof, vitamin C or Examples thereof include vitamin E or a derivative thereof or a salt thereof.
- antifoaming agent examples include dimethylpolysiloxane.
- antiemetics include, for example, granisetron, domperidone, sulpiride, ondansetron, azasetron, dimenhydrinate, metoclopramide, chlorpromazine, diphenidol hydrochloride, diphenhydramine, diphenhydramine hydrochloride, meclizine, promethazine, chlorpheniramine, chlorpheniline maleate Lamin, amphetamine, atropine, bromvalerylurea, allylisopropylacetylurea, caffeine, theophylline, mint oil, menthol, vitamin B6 and the like can be mentioned.
- Additives include physiologically excipients, binders, disintegrants, lubricants, stabilizers, thickeners, solubilizers, preservatives, pH adjusters, colorants, sweeteners, etc. There are various acceptable types.
- excipient examples include lactose, starches, crystalline cellulose, sucrose, mannitol, light anhydrous silicic acid and the like.
- binder examples include hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol, pullulan and the like.
- disintegrant examples include carmellose, carmellose calcium, croscarmellose sodium, crospovidone, corn starch, and low-substituted hydroxypropylcellulose.
- Examples of the lubricant include magnesium stearate and talc.
- the stabilizer examples include ascorbic acid, edetic acid, and salts thereof.
- thickener examples include carmellose sodium, agar, gelatin, polyvinyl alcohol, polyvinyl pyrrolidone and the like.
- solubilizer examples include nonionic surfactants such as hydrogenated oil, glyceryl monostearate, polyoxyethylene hydrogenated castor oil, and sucrose fatty acid ester, and lecithin.
- preservative examples include benzoic acid, sodium benzoate, methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, isopropyl paraoxybenzoate, butyl paraoxybenzoate, isobutyl paraoxybenzoate and the like.
- pH adjuster examples include citric acid, malic acid, lactic acid, tartaric acid, acetic acid, hydrochloric acid, phosphoric acid, and salts thereof, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, and the like.
- Examples of the colorant include titanium oxide, tar pigment, yellow No. 4, yellow No. 5, ferric oxide, yellow ferric oxide, red No. 3 and the like.
- sweetening agent examples include sucrose, liquid sugar, fructose, fructose glucose liquid sugar, reduced maltose water candy, honey, caramel, sorbitol, maltitol, xylitol, erythritol, sucralose, stevia, glycyrrhizic acid or a salt thereof, aspartame, acesulfame Potassium etc. are mentioned.
- the gastrointestinal mucosa protective agent or antiemetic of the present invention can be taken alone, or it can be contained in a pharmaceutical composition together with other active ingredients and additives, or in the form of a food additive or food supplement. It can also be used as a health food and drink by containing it in various foods and drinks. Moreover, according to the objective of this invention, it can manufacture in dosage forms, such as a liquid agent, a powder, a granule, a tablet, a chewable tablet, a film-coated tablet, a sugar-coated tablet, a soft capsule, a hard capsule, and a jelly agent by a well-known and usual technique.
- the gastrointestinal mucosal protective agent of the present invention pharmaceuticals or foods and drinks containing the same are used to improve gastrointestinal mucosal damage caused by alcohol consumption, stress, overdrinking, smoking, and taking non-steroidal anti-inflammatory drugs, etc.
- An indication that it is used for prevention may be attached. For example, indications such as “to prevent or alleviate stomach pain, nausea, stomach weight, etc.”, “drink before drinking alcohol to prevent nausea”, “energetic next day after drinking”, etc.
- such a display can be attached to the container packaging means by a known method, whereby the gastrointestinal mucosa protective agent of the present invention, the pharmaceutical or food or drink containing the same, alcohol intake, stress, overdrinking, Since it is clearly stated that it is used for the improvement and / or prevention of gastrointestinal mucosal damage caused by smoking and taking non-steroidal anti-inflammatory drugs, etc. Becomes clear.
- the antiemetic of the present invention medicines or foods and drinks containing the same may be labeled for use in the improvement and / or prevention of nausea, nausea or vomiting caused by alcohol consumption.
- indications such as “to prevent or relieve nausea, nausea and vomiting”, “prevent nausea by drinking before drinking”, “energetic next day after drinking”, etc.
- a display can be attached to the container and packaging means by a publicly known method, whereby the antiemetic of the present invention, a medicine containing the same, or a food or drink can improve various symptoms caused by alcohol intake and / or Or, since it is clearly indicated that it is used for prevention, the distinction from normal agents, pharmaceuticals or foods and drinks becomes clear.
- Test Example 1 Effect on gastric mucosal damage model A Wistar male rat (8 weeks old) fasted overnight with a suspension of the test substance in physiological saline (but only physiological saline as a control) Oral administration (5 mL / kg) was performed, and 30 minutes later, 99.5 vol% ethanol was orally administered at 1 mL / animal. One hour after ethanol administration, the stomach was removed, fixed with 1% by volume formalin, the stomach was cut open, and the length of damage (damage factor) occurring in the gastric mucosa was measured.
- test substances were control (saline), turmeric powder (autumn turmeric) 600 mg / kg, chickweed powder (Jawa Naga pepper) 150 mg / kg, and turmeric powder (autumn turmeric) 600 mg / kg + hihatsu powder (Jawa Naga pepper) )
- test substances were control (saline), turmeric powder (autumn turmeric) 600 mg / kg, chickweed powder (Jawa Naga pepper) 150 mg / kg, and turmeric powder (autumn turmeric) 600 mg / kg + hihatsu powder (Jawa Naga pepper) )
- Four groups of 150 mg / kg combined. The result of the gastric mucosa damage inhibitory effect when each test substance is administered is shown in FIG.
- turmeric powder 600 mg / kg suppressed the occurrence of ulcers
- hihatsu powder 150 mg / kg exhibited an antiulcer action superior to that of the control.
- a further superior anti-ulcer action was confirmed as compared with chickpea powder 150 mg / kg alone.
- the average ulcer index of each group was 0.50 in the turmeric powder group and 0.26 in the chickweed powder group when the control was 1, and the product (0.13) was 0.
- turmeric The anti-ulcer action of baboon was greatly promoted by combined use with turmeric (Burgi method: Keijiro Takagi et al .: Pharmacology, 1987, Nanzan-do). From the above, it was shown that both turmeric and baboon have excellent gastric mucosal protective action against gastric mucosal damage caused by ethanol intake. It was also shown that when turmeric and hihatsu were administered in combination, both components acted synergistically to provide an excellent gastric mucosa protective effect. In this example, in order to create a gastric mucosal damage model, ethanol was used to induce ulcers, but not limited to ethanol, such as stress, heavy drinking and eating, smoking, and after taking nonsteroidal anti-inflammatory drugs, etc. It has the same effect on ulcers caused by factors.
- Example 1 Preparation of a Japanese pine plant formulation To 10 mL of purified water, 50 mg of pine powder, 45 mg of oxoamidin powder, 135 mg of carrot dry extract, 200 mg of turmeric powder, 0.3 mL of lauren extract, 100 mg of dried gentian powder, 82 mg of licorice extract powder were added. (Formulation liquid 1). Separately, 1.5 g of purified white sugar and 0.09 g of polyvinylpyrrolidone were added to 10 mL of purified water, and this was heated and dissolved. This liquid was mixed with the preparation liquid 1 prepared above, and sodium citrate was added to adjust the pH to 5. An appropriate amount of purified water was added thereto to make a total volume of 50 mL to obtain an internal solution.
- Formulation liquid 1 Separately, 1.5 g of purified white sugar and 0.09 g of polyvinylpyrrolidone were added to 10 mL of purified water, and this was heated and dissolved. This liquid was mixed with the preparation liquid 1
- Comparative Example 1 Preparation of a non-hihatsu formulation Water was used as a control.
- Comparative Example 2 Preparation of non-hihatsu formulation Solmac Plus (Takuma Pharmaceutical Co., Ltd.) was used.
- Solmac Plus includes turmeric extract 0.3 mL, licorice extract 135 mg, carrot extract 0.5 mL, aurin tincture 0.826 mL, clove tincture 0.126 mL, gentian tincture 0.376 mL, and sojutsu extract 1.2 mL, cinnamon tincture 0.25 mL, and carnitine chloride 120 mg are blended.
- Test Example 2 Evaluation of antiemetic effect Obtained in Example 1, Comparative Example 1 or Comparative Example 2 using an 11-month-old male Suncus (Suncus murinus) that was given food (CIEA-312) and water freely.
- n 6 for each group.
- 40% ethanol was further orally administered to 5 mg / kg, and the vomiting reaction to the test sunx was observed for 60 minutes after ethanol administration. In this experiment, when there was vomiting of the stomach contents, it was considered that there was a vomiting reaction.
- Example 1 containing hihatsu had fewer vomiting times than Comparative Examples 1 and 2.
- the time to show vomiting reaction was also reduced. Based on these results, it was shown that the inclusion of baboon has the effect of suppressing the vomiting reaction itself, not the delay of the vomiting reaction, and can contribute to quick recovery from unpleasant conditions such as nausea, nausea or vomiting. .
- the following production examples 1 to 4 show production examples of the gastrointestinal mucosa protective agent or antiemetic of the present invention.
- 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), carrot A kneaded product was prepared by adding 800 parts by mass of 70% ethanol to a mixed powder comprising 20 parts by mass of a dry extract, 70 parts by mass of polyvinyl alcohol, 30 parts by mass of carmellose calcium, 40 parts by mass of crystalline cellulose, and 1545 parts by mass of xylitol.
- the kneaded product was extruded and granulated ( ⁇ 0.8 mm), dried, sized and classified to obtain granules (hereinafter referred to as B granules). Further, 6 parts by mass of L-menthol was adsorbed on 24 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granule, 3405 parts by mass of B granule, and 30 parts by mass of C fragrance powder were mixed by a mixer, and further packed by a packaging machine to obtain a granule having a single dose of 1.2 g.
- 450 parts by weight of dry aluminum hydroxide gel, 325 parts by weight of magnesium hydroxide, 450 parts by weight of synthetic hydrotalcite, 75 parts by weight of licorice extract powder, 200 parts by weight of fennel powder, 200 parts by weight of turmeric powder (autumn turmeric), show Add 700 parts by mass of 90% ethanol to a mixed powder consisting of 100 parts by mass of carp powder, 20 parts by mass of dried carrot extract, 90 parts by mass of hydroxypropyl cellulose, 30 parts by mass of carmellose calcium, 30 parts by mass of crystalline cellulose, and 1445 parts by mass of erythritol. A kneaded product was made.
- the kneaded product was dried and sized to obtain granules (hereinafter referred to as B granules). Further, 4 parts by mass of L-menthol was adsorbed on 16 parts by mass of magnesium aluminate metasilicate to obtain a fragrance powder (hereinafter referred to as C fragrance powder). 165 parts by mass of A granules, 3415 parts by mass of B granules, and 20 parts by mass of C fragrance powder were mixed with a mixer, and further packaged with a packaging machine to obtain a granule having a single dose of 1.2 g.
- the gastrointestinal protective agent of the present invention contains baboon, gastrointestinal mucosal damage or peptic ulcer caused by excessive intake of ethanol, stress, violent eating and eating, smoking, and taking non-steroidal anti-inflammatory drugs, etc. Has an excellent preventive and / or therapeutic effect. Furthermore, a synergistic effect is acquired by using turmeric together. Moreover, the antiemetic of this invention has the antiemetic effect excellent with respect to nausea, nausea, or vomiting by containing a hihatsu. In particular, it has an excellent antiemetic action against nausea, nausea or vomiting caused by excessive intake of alcohol, and these symptoms can be quickly improved.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
特に、吐き気、悪心又は嘔吐を伴うほど過剰にエタノールを摂取してしまった場合、身体的な苦痛が大きく、回復までにより長い時間が必要になる。そのため、エタノールの過剰摂取による吐き気、悪心又は嘔吐に対して優れた鎮吐作用を有する薬剤の提供が望まれている。
また、ヒハツがエタノールの過剰摂取等による吐き気、悪心又は嘔吐に対してどのような影響を与えるかについては知られていない。
また、本発明は、エタノールの過剰摂取等による吐き気、悪心又は嘔吐に対して優れた鎮吐作用を有する薬剤を提供することを目的とする。
すなわち、本発明は、ヒハツを含有する消化管粘膜保護剤(以下、本発明の消化管粘膜保護剤と呼ぶ)を提供するものである。また、本発明は、ヒハツを含有する鎮吐剤(以下、本発明の鎮吐剤と呼ぶ)を提供するものである。
また、本発明によれば、吐き気、悪心又は嘔吐に対して優れた改善作用を有する鎮吐剤を提供することができる。より詳細には、エタノール摂取によってもたらされる吐き気、悪心又は嘔吐に対して優れた改善作用を有する鎮吐剤を提供することができる。
本発明は、特にエタノール摂取によりもたらされる消化管粘膜障害及び嘔吐に対して優れた改善作用を有するため、これらのエタノール摂取による不快症状の改善剤として有効に利用できる。
本発明においてヒハツとは、コショウ科に属するヒハツ(Piper longum L.(別名:インドナガコショウ)又はPiper retrofractum Vahl(別名:ジャワナガコショウ、ヒハツモドキ))を意味する。
なお、ヒハツはナガコショウ(ロングペッパー)とも呼ばれ、植物分類学的に、狭義にはインドナガコショウをヒハツとし、それと区別するためにジャワナガコショウをヒハツモドキとする文献もあるが、本発明では両方をヒハツとして扱う。
上記のヒハツは、成熟した、または未成熟の果穂、葉、葉柄、枝、根等を原料としたものが用いられる。
本発明で使用するヒハツは、その果穂又は未成熟果穂であることが好ましい。これらは、適宜、乾燥させて粉末にしたヒハツ末や、水、低級アルコール又はそれらの混合溶媒で抽出した抽出エキスとしたものを使用できる。具体的には、ヒハツ、ヒハツ末、ヒハツエキス、ヒハツ流エキス、ヒハツ乾燥エキス、ヒハツ軟稠エキス等が挙げられ、ヒハツ末であることが好ましい。市販品としては、例えば、ヒハツ末(三國株式会社製)、ヒハツエキスMF(丸善製薬株式会社製)等が挙げられる。
本発明で使用するヒハツは、製剤に対して原生薬換算量で0.001~10重量%であるのが好ましく、0.01~5重量%であるのがさらに好ましい。この配合量が0.001重量%未満では、効果が低くなる場合があり、10重量%を超えると辛み等の刺激が強くなり、服用感の面で好ましくない場合がある。
なお、成人1日当りのヒハツの使用量は原生薬換算量で通常5g/日、好ましくは3g/日までの範囲で使用できるが、1回服用量は、原生薬換算量で通常0.001~2g、好ましくは0.01~1gの範囲にすることが好ましい。
本発明で使用するウコンは、根茎をそのまま、又は周皮を除き湯通ししたものであることが好ましく、さらにそれを乾燥させて粉末にしたウコン末や、水、低級アルコール又はそれらの混合溶媒で抽出した抽出エキスにしたものがさらに好ましい。具体的には、ウコン、ウコン末、ウコンエキス、ウコン流エキス、ウコン乾燥エキス、ウコン軟稠エキス、発酵ウコン等が挙げられ、ウコン末又はウコン流エキスであることが好ましい。市販品としては、例えば、ウコン末(日本粉末薬品株式会社製)、ウコン流エキス(日本粉末薬品株式会社製、丸善製薬株式会社製)等が挙げられる。
なお、成人1日当りのウコンの使用量は原生薬換算量で通常10g/日、好ましくは6g/日までの範囲で使用できるが、1回服用量は、原生薬換算量で通常0.01~6g、好ましくは0.1~2gの範囲にすることが好ましい。
ここで、吐き気、悪心又は嘔吐の原因又は疾患としては、エタノールの過剰摂取、ストレス、乗り物酔い、食中毒、体の冷え、妊娠(つわり)、異物の誤飲、薬による副作用、急性胃炎、胃・十二指腸潰瘍、虫垂炎、腸閉塞、急性腹膜炎、膵炎、片頭痛、メニエール病、脳出血、脳腫瘍、くも膜下出血、急性胆のう炎、急性肝炎、アルコール性肝炎、胆石症、胃ポリープ、脂肪肝、肺炎、緑内障、又は慢性硬膜下血腫等が挙げられる。
本発明の鎮吐剤においては、特にエタノールの過剰摂取により、血中エタノールの分解が間に合わずにエタノール代謝物が嘔吐中枢を刺激することにより引き起こされる吐き気、悪心又は嘔吐に対して優れた抑制又は予防効果が認められる。
なお、本明細書においてアルコールはエタノールと同義とする。
なお、このような表示は、公知の方法で容器包装手段に付すことができ、これによって本発明の消化管粘膜保護剤、これを含有する医薬品又は飲食品は、アルコール摂取、ストレス、暴飲暴食、喫煙、及び、非ステロイド性抗炎症薬の服用等に起因する消化管粘膜障害の改善及び/又は予防のために用いられるものであることが明示されるので、通常の剤又は飲食物との区別が明確となる。
なお、このような表示は、公知の方法で容器包装手段に付すことができ、これによって本発明の鎮吐剤、これを含有する医薬品又は飲食品は、アルコール摂取に起因する諸症状の改善及び/又は予防のために用いられるものであることが明示されるので、通常の剤、医薬品又は飲食物との区別が明確となる。
被験物質を生理食塩水で懸濁したもの(但し、コントロールでは生理食塩水のみ)を、一晩絶食したウィスター(Wistar)系雄性ラット(8週齢) に経口投与(5mL/kg)し、その30分後に99.5体積%エタノールを1mL/匹ずつ経口投与した。エタノール投与から1時間後に胃を摘出し、1体積%ホルマリンで固定した後、胃を切り開き、胃粘膜に発生した損傷の長さ(損傷係数)を測定した。なお、被験物質は、コントロール(生理食塩水)、ウコン末(秋ウコン)600mg/kg、ヒハツ末(ジャワナガコショウ)150mg/kg、およびウコン末(秋ウコン)600mg/kg+ヒハツ末(ジャワナガコショウ)150mg/kg併用の4群である。各被験物質を投与した際の胃粘膜損傷抑制効果の結果を図1に示す。
本実施例では、胃粘膜損傷モデルを作製するために、エタノールを用いて潰瘍を誘発したが、エタノールに限らず、ストレス、暴飲暴食、喫煙、及び、非ステロイド性抗炎症薬の服用後等の要因による潰瘍にも同様の効果を奏する。
精製水10mLに、ヒマツ末50mg、オキソアミヂン末45mg、ニンジン乾燥エキス135mg、ウコン末200mg、オウレン流エキス0.3mL、ゲンノショウコ乾燥エキス100mg、カンゾウエキス末82mgを加えた(調合液1)。これとは別に精製水10mLに、精製白糖1.5g、ポリビニルピロリドン0.09gを加え、これを加温して溶解させた。この液を、前記で調合した調合液1と混合し、クエン酸ナトリウムを加え、pHを5に調整した。これに精製水適量を加えて全量50mLとして内服液剤を得た。
コントロールとして水を使用した。
ソルマックプラス(大鵬薬品工業(株))を使用した。なお、ソルマックプラスには、50mL中にウコン流エキス0.3mL、カンゾウ抽出物135mg、ニンジン流エキス0.5mL、オウレンチンキ0.826mL、チョウジチンキ0.126mL、ゲンチアナチンキ0.376mL、ソウジュツ流エキス1.2mL、ケイヒチンキ0.25mL、カルニチン塩化物120mgが配合されている。
自由に餌(CIEA-312)及び水を与えられていた11カ月齢の雄性スンクス(Suncus murinus)を用い、実施例1、比較例1又は比較例2で得られた薬剤試料をそれぞれ20mL/kg、20mL/kg、10mL/kgとなるように経口投与した(各群n=6)。その10分後、さらに40%エタノールを5mg/kgとなるように経口投与し、エタノール投与から60分間の被験スンクスに対する嘔吐反応を観察した。なお、本実験では胃の内容物の嘔吐があった場合に、嘔吐反応があったとみなした。エタノール投与から60分後までの嘔吐回数、嘔吐開始時間、及び嘔吐反応持続時間を計測し、その結果を表1にまとめた。
本実験において、実験動物(スンクス)の飼育・管理に関する一般的な取り扱いは、The Guide for the Care and Use of Laboratory Animals(National Academy Press, Washington,D.C.,2010)に従った。
精製水(80~90℃)500Lに安息香酸ナトリウム500g及びパラオキシ安息香酸エチル40g、精製白糖70kg、カルメロースナトリウム3kgを加え、攪拌しながら溶解させた。この液を冷却後、硝酸チアミン377g及びリン酸水素ナトリウム100gを加え、攪拌しながら溶解させる。別に精製水(80~90℃)200Lに人参乾燥エキス1.4kg(人参として20kg)及びヒハツ末(ジャワナガコショウ)0.5kg、ショウキョウエキス970g(ショウキョウとして10kg)、ウコン流エキス11L(秋ウコンとして11kg)、クエン酸1.5kg、酒石酸1.5kgを加え、攪拌溶解した液を冷却後、ろ過した。これら2液を混合した後、ハッカ油167g及びウイキョウ油33g、チョウジ油33gを加え、攪拌しながら混合した。この混合液に精製水を適量加え、全量を1000Lとすることにより、内服液を製した。
精製水(80~90℃)500Lに安息香酸ナトリウム0.7kg及びパラオキシ安息香酸ブチル0.14kg、精製白糖70kg、カルメロースナトリウム6kgを加え、攪拌しながら溶解させた。この液を冷却後、人参乾燥エキス1.8kg(人参として25kg)及びヒハツ末(ジャワナガコショウ)3kg、ショウキョウ流エキス6L(ショウキョウとして6kg)、ウコン流エキス6L(秋ウコンとして6kg)、ウイキョウ流エキス6L(ウイキョウとして6kg)、チョウジ流エキス6L(チョウジとして6kg)、香料0.5Lを加え、攪拌溶解した。別に精製水(80~90℃)300Lに合成ヒドロタルサイト6kgを加え、攪拌混合した後、高圧ホモゲナイザーで循環分散した。分散液を冷却後、先の混合液と合わせたものに精製水を適量加え、全量を1000Lとすることにより、内服液を調製した。
ヒハツ末(ジャワナガコショウ)40質量部、ビタミンB1 25質量部、硬化油50質量部、モノステアリン酸グリセリン20質量部、トウモロコシデンプン15質量部、カルメロースカルシウム15質量部からなる混合末にエタノール12質量部を加え練合物を製した。練合物を押出し造粒し(φ0.8mm)、乾燥、整粒、分級し顆粒を得た(以下A顆粒と称する)。
また、乾燥水酸化アルミニウムゲル450質量部、水酸化マグネシウム325質量部、合成ヒドロタルサイト450質量部、カンゾウエキス末75質量部、ウイキョウ末200質量部、ウコン末(秋ウコン)200質量部、ニンジン乾燥エキス20質量部、ポリビニルアルコール70質量部、カルメロースカルシウム30質量部、結晶セルロース40質量部、キシリトール1545質量部からなる混合末に70%エタノール800質量部を加え練合物を製した。練合物を押出し造粒し(φ0.8mm)、乾燥、整粒、分級し、顆粒を得た(以下B顆粒と称する)。
さらにメタケイ酸アルミン酸マグネシウム24質量部にL-メントール6質量部を吸着させ、香料末を得た(以下C香料末と称する)。
A顆粒165質量部、B顆粒3405質量部、C香料末30質量部を混合機にて混合し、さらに分包機にて分包し1回服用量1.2gの顆粒剤を得た。
ヒハツ末(ジャワナガコショウ)30質量部、ビタミンB1 25質量部、硬化油55質量部、モノステアリン酸グリセリン25質量部、トウモロコシデンプン15質量部、カルメロースカルシウム15質量部からなる混合末にエタノール12質量部を加え練合物を製した。練合物を押出し造粒し(φ0.5mm)、乾燥、整粒し顆粒を得た(以下A顆粒と称する)。
また、乾燥水酸化アルミニウムゲル450質量部、水酸化マグネシウム325質量部、合成ヒドロタルサイト450質量部、カンゾウエキス末75質量部、ウイキョウ末200質量部、ウコン末(秋ウコン)200質量部、ショウキョウ末100質量部、ニンジン乾燥エキス20質量部、ヒドロキシプロピルセルロース90質量部、カルメロースカルシウム30質量部、結晶セルロース30質量部、エリスリトール1445質量部からなる混合末に90%エタノール700質量部を加え練合物を製した。練合物を乾燥、整粒し顆粒を得た(以下B顆粒と称する)。
さらにメタケイ酸アルミン酸マグネシウム16質量部にL-メントール4質量部を吸着させ、香料末を得た(以下C香料末と称する)。
A顆粒165質量部、B顆粒3415質量部、C香料末20質量部を混合機にて混合し、さらに分包機にて分包し1回服用量1.2gの顆粒剤を得た。
また、本発明の鎮吐剤は、ヒハツを含有することにより、吐き気、悪心又は嘔吐に対して優れた鎮吐作用を有する。特に、アルコールの過剰摂取によりもたらされる吐き気、悪心又は嘔吐に対して優れた鎮吐作用を有し、これらの症状を速やかに改善できる。
Claims (9)
- ヒハツを含有する消化管粘膜保護剤。
- さらにウコンを含有する、請求項1に記載の消化管粘膜保護剤。
- エタノールによる消化管粘膜障害を抑制するものである、請求項1又は2に記載の消化管粘膜保護剤。
- エタノールによる消化管粘膜障害が、エタノール摂取後の胃痛、むかつき又は胃重である、請求項1~3のいずれか1項に記載の消化管粘膜保護剤。
- 前記消化管粘膜が、胃粘膜又は十二指腸粘膜である、請求項1~4のいずれか1項に記載の消化管粘膜保護剤。
- 請求項1~5のいずれか1項に記載の消化管粘膜保護剤を含有する医薬品又は飲食品。
- ヒハツを含有する鎮吐剤。
- エタノール摂取によりもたらされる吐き気、悪心又は嘔吐に対するものである、請求項7に記載の鎮吐剤。
- 請求項7又は8に記載の鎮吐剤を含有する医薬品又は飲食品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014524859A JPWO2014010658A1 (ja) | 2012-07-11 | 2013-07-11 | ヒハツ配合製剤 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012-155663 | 2012-07-11 | ||
| JP2012-155659 | 2012-07-11 | ||
| JP2012155663 | 2012-07-11 | ||
| JP2012155659 | 2012-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014010658A1 true WO2014010658A1 (ja) | 2014-01-16 |
Family
ID=49916099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2013/068934 Ceased WO2014010658A1 (ja) | 2012-07-11 | 2013-07-11 | ヒハツ配合製剤 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2014010658A1 (ja) |
| WO (1) | WO2014010658A1 (ja) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015077124A (ja) * | 2013-09-13 | 2015-04-23 | 大正製薬株式会社 | 飲料 |
| JP2017537944A (ja) * | 2014-12-12 | 2017-12-21 | アリ ヘルスケア ピーブイティー リミテッドAri Healthcare Pvt. Ltd. | 口内リフレッシャー |
| CN109453362A (zh) * | 2019-01-16 | 2019-03-12 | 汤臣倍健股份有限公司 | 一种保护胃黏膜及抗幽门螺旋杆菌的组合物及其应用 |
| JP2019202995A (ja) * | 2018-05-17 | 2019-11-28 | 大正製薬株式会社 | 経口組成物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58162520A (ja) * | 1982-03-23 | 1983-09-27 | Res Inst For Prod Dev | 抗潰瘍剤 |
| JP2005526791A (ja) * | 2002-03-25 | 2005-09-08 | カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ | 胃潰瘍を治療するための組成物およびそれを製造するための方法 |
| JP2006104109A (ja) * | 2004-10-04 | 2006-04-20 | Maruzen Pharmaceut Co Ltd | むくみ感改善剤及びむくみ感改善用飲食物 |
| JP2011184381A (ja) * | 2010-03-10 | 2011-09-22 | Maruzen Pharmaceut Co Ltd | アデノシン三リン酸産生促進剤及びアデノシン三リン酸産生量低下に起因する疾患の予防・治療剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003226650A (ja) * | 2001-11-30 | 2003-08-12 | Daito Kk | 医薬用組成物 |
-
2013
- 2013-07-11 WO PCT/JP2013/068934 patent/WO2014010658A1/ja not_active Ceased
- 2013-07-11 JP JP2014524859A patent/JPWO2014010658A1/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58162520A (ja) * | 1982-03-23 | 1983-09-27 | Res Inst For Prod Dev | 抗潰瘍剤 |
| JP2005526791A (ja) * | 2002-03-25 | 2005-09-08 | カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ | 胃潰瘍を治療するための組成物およびそれを製造するための方法 |
| JP2006104109A (ja) * | 2004-10-04 | 2006-04-20 | Maruzen Pharmaceut Co Ltd | むくみ感改善剤及びむくみ感改善用飲食物 |
| JP2011184381A (ja) * | 2010-03-10 | 2011-09-22 | Maruzen Pharmaceut Co Ltd | アデノシン三リン酸産生促進剤及びアデノシン三リン酸産生量低下に起因する疾患の予防・治療剤 |
Non-Patent Citations (5)
| Title |
|---|
| "Protective action of piperine against experimental gastric ulcer.", ACTA PHARMACOLOGICA SINICA, vol. 21, no. 4, 2000, pages 357 - 359 * |
| HISASHI MATSUDA ET AL.: "Gastroprotective Constituents from Several Spices and Their Structural Requirements for the Activity and Mode of Action : Tasmannia lanceolata, Alpinia galanga, Piper chaba, and Boesenbergia rotunda", SYMPOSIUM ON THE CHEMISTRY OF NATURAL PRODUCTS, SYMPOSIUM PAPERS, vol. 46, 1 September 2004 (2004-09-01), pages 611 - 615 * |
| KATSUYUKI SASAHARA ET AL.: "Examination of changes in energy metabolism in gastric mucosa and quantity of mucus influenced by administration of adenosine triphosphate in patients of chronic gastritis", RINSHO TO KENKYU, vol. 76, no. 10, 1999, pages 185 - 188 * |
| SHOGAKUKAN INC.,, CHUYAKU DAIJITEN, 1ST EDITION, 10 December 1985 (1985-12-10), pages 2227 - 2228 * |
| T MORIKAWA ET AL.: "New amides and gastroprotective constituents from the fruit of Piper chaba.", PLANTA MED., vol. 70, no. 2, 2004, pages 152 - 159 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015077124A (ja) * | 2013-09-13 | 2015-04-23 | 大正製薬株式会社 | 飲料 |
| JP2020150953A (ja) * | 2013-09-13 | 2020-09-24 | 大正製薬株式会社 | 飲料 |
| JP2017537944A (ja) * | 2014-12-12 | 2017-12-21 | アリ ヘルスケア ピーブイティー リミテッドAri Healthcare Pvt. Ltd. | 口内リフレッシャー |
| JP2019202995A (ja) * | 2018-05-17 | 2019-11-28 | 大正製薬株式会社 | 経口組成物 |
| JP7283216B2 (ja) | 2018-05-17 | 2023-05-30 | 大正製薬株式会社 | 経口組成物 |
| CN109453362A (zh) * | 2019-01-16 | 2019-03-12 | 汤臣倍健股份有限公司 | 一种保护胃黏膜及抗幽门螺旋杆菌的组合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2014010658A1 (ja) | 2016-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2002096406A1 (ja) | 医薬組成物 | |
| JP5679721B2 (ja) | 漢方エキスを含有する医薬組成物 | |
| JP6345243B2 (ja) | 円武扇発酵物含有食品または飲料組成物 | |
| JP2014015430A (ja) | 深部体温上昇剤 | |
| JPWO2014010656A1 (ja) | 優れた血中アルコール濃度低下促進剤 | |
| WO2014010658A1 (ja) | ヒハツ配合製剤 | |
| US8158171B2 (en) | Methods of lowering blood cholesterol via oral fenugreek seed extract compositions | |
| JP4667244B2 (ja) | 医薬組成物 | |
| KR101910013B1 (ko) | 한약재 추출물(socg)을 함유하는 통증의 개선, 예방 또는 치료용 조성물 | |
| JP5187935B2 (ja) | 羅漢果エキスを含有する創傷治癒促進組成物と適用方法 | |
| KR101528557B1 (ko) | 천년초 발효물 함유 의약 조성물 | |
| JP6771274B2 (ja) | 内服用組成物 | |
| JP2008056567A (ja) | 胃腸疾患の治療又は予防のための医薬 | |
| JP5823131B2 (ja) | 防風通聖散含有組成物 | |
| WO2017084631A9 (zh) | 预防或治疗脂肪胰、改善脂肪胰引起的胰病变、糖尿病或其他相关病症之组合物及方法 | |
| JP2005162713A (ja) | 内服用組成物 | |
| KR20200140103A (ko) | 틱장애, 뚜렛증후군 또는 강박장애의 예방 또는 치료용 조성물 | |
| WO2020008359A1 (en) | A formulation for the prevention and as a coadjuvant treatment of neurodegenerative diseases | |
| JP7263151B2 (ja) | 経口組成物 | |
| JP6114133B2 (ja) | クコシエキス含有内服液剤、可溶化剤および可溶化方法 | |
| JP4950551B2 (ja) | 消化管粘膜保護剤 | |
| JP7452777B2 (ja) | 生活の質改善又は維持用組成物 | |
| JP2003342186A (ja) | 鼻炎用内服液剤組成物 | |
| JP7369931B2 (ja) | 風邪症状緩和用飲食品組成物 | |
| JP2004091420A (ja) | 内服用医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13816312 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2014524859 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2015/00276 Country of ref document: TR |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 13816312 Country of ref document: EP Kind code of ref document: A1 |
